{"filing":{"accession_number":"0001841387-26-000007","cik":"0001841387","ticker":"CADL","company_name":"Candel Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"cadl-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1841387/000184138726000007/cadl-20260612.htm"},"events":[{"id":11332,"run_id":9948,"accession_number":"0001841387-26-000007","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The disclosure centers on a new employment agreement with Charles Schoch, the CFO, setting forth compensatory arrangements including base salary ($468,600), annual bonus (40% target), severance provisions (nine months base plus target bonus), COBRA continuation, and equity acceleration upon change of control. This is a classic executive compensation arrangement disclosure under Item 5.02(e), material because it establishes the CFO's compensation terms and change-of-control protections.","company_name":"Candel Therapeutics, Inc.","ticker":"CADL","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7897,"accession_number":"0001841387-26-000007","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on a new employment agreement with Charles Schoch, the CFO, setting forth compensatory arrangements including base salary ($468,600), annual bonus (40% target), severance provisions (nine months base plus target bonus), COBRA continuation, and equity acceleration upon change of control. This is a classic executive compensation arrangement disclosure under Item 5.02(e), material because it establishes the CFO's compensation terms and change-of-control protections.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:25:06.562103+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7897,"accession_number":"0001841387-26-000007","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on a new employment agreement with Charles Schoch, the CFO, setting forth compensatory arrangements including base salary ($468,600), annual bonus (40% target), severance provisions (nine months base plus target bonus), COBRA continuation, and equity acceleration upon change of control. This is a classic executive compensation arrangement disclosure under Item 5.02(e), material because it establishes the CFO's compensation terms and change-of-control protections.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:25:06.562103+00:00","company_name":"Candel Therapeutics, Inc.","ticker":"CADL","filing_date":"2026-06-16"}]}